Cervical cancer is the leading cause of cancer deaths of women in
developing world. Several studies demonstrated evidences of inflammatory
cytokines implication in cancer progression including in initiation, promotion
and invasion by affecting the immune surveillance. Our aim was to measure blood
circulating pro- and anti-inflammatory cytokines levels, their profiles
according to treatment issue and relation with prognostic factors in cervical
cancer during chemotherapy. Blood samples were collected from a cohort of 35
cervical cancer women and 42 women healthy controls (HC) with no history of
malignancy. For each CP, three samples were taken at three-week intervals. The
first one (S1) was taken before initiation of the chemotherapy protocol. S2 and
S3 were samples collected respectively at day 21 and day 42. Cytokines levels
were evaluated by ELISA. Mean age of patients was 54.1 year (35 - 77 yo). In groups, no relation
was observed between age and cytokines levels. Before chemotherapy, high levels
of IL-6, IL-4 and IFN-γ were observed
in CP compared to HC (p < 0.001)and at the same period, IL-10 and TNF-α levels were significantly low in CP (p
< 0.05) andnegatively correlated (r =？—0.79; p=0.017). In this CP group,
IL-4 levels were positively correlated between S1 and S2 (r =0.72; p=0.002) and between S1 and S3 (r =0.74; p =0.019).
Similar correlations were observed for TNF-α levels: S1/S2(r =0.54; p =0.027), S2/S3 (r =0.82; p =0.009)
and S1/S3 (r =0.66; p =0.036) with a significant
increase of TNF-α in blood during
treatment. Depending on chemotherapy’s efficacy, CP patients were separated
into 1) non responders (NR), 2) partial responders (PR) and 3) good responders
(GR). Compared to PR and GR groups, NR patients showed: a) higher serum levels of
IL-6, IL-10
References
[1]
Bray, F., Ferlay, J. and Soerjomataram, I. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
Crosbie, E.J., Einstein, M.H. and Franceschi, S. (2013) Human Papillomavirus and Cervical Cancer. The Lancet, 382, 889-899. https://doi.org/10.1016/S0140-6736(13)60022-7
[3]
ICO (2019) Information Centre on HPV and Cancer HPV Information Centre.
[4]
NCCN (2020) Cervical Cancer.
[5]
De Sanjose, S., Quint, W.G.V. and Alemany, L. (2010) Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: A Retrospective Cross-Sectional Worldwide Study. The Lancet Oncology, 11, 1048-1056. https://doi.org/10.1016/S1470-2045(10)70230-8
[6]
Hu, X., Schwarz, J.K. and Lewis, J.S.A. (2010) microRNA Expression Signature for Cervical Cancer Prognosis. Cancer Research, 70, 1441-1448. https://doi.org/10.1158/0008-5472.CAN-09-3289
[7]
Stevanović, S., Draper, L.M. and Langhan, M.M. (2015) Complete Regression of Metastatic Cervical Cancer after Treatment with Human Papillomavirus-Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology, 33, 1543. https://doi.org/10.1200/JCO.2014.58.9093
[8]
Denny, L. (2012) Cervical Cancer: Prevention and Treatment. Discovery Medicine, 14, 125-131.
[9]
Peters, W.A., Liu, P.Y. and Barrett, R.J.I. (2000) Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy after Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Journal of Clinical Oncology, 18, 1606-1613. https://doi.org/10.1200/JCO.2000.18.8.1606
[10]
Whitney, C.W., Sause, W. and Bundy, B.N. (1999) Randomized Comparison of Fluorouracil plus Cisplatin versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix with Negative Paraaortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. Journal of Clinical Oncology, 17, 1339-1348. https://doi.org/10.1200/JCO.1999.17.5.1339
[11]
Zhu, L., Zhang, X. and Sun, Z. (2020) SNRPB Promotes Cervical Cancer Progression through Repressing p53 Expression. Biomedicine & Pharmacotherapy, 125, Article ID: 109948. https://doi.org/10.1016/j.biopha.2020.109948
[12]
Bidwell, J., Keen, L. and Gallagher, G. (2001) Cytokine Gene Polymorphism in Human Disease: On-Line Databases, Supplement 1. Genes & Immunity, 2, 61-70. https://doi.org/10.1038/sj.gene.6363733
[13]
Haukim, N., Bidwell, J.L. and Smith, A.J.P. (2002) Cytokine Gene Polymorphism in Human Disease: On-Line Databases, Supplement 2. Genes & Immunity, 3, 313-330. https://doi.org/10.1038/sj.gene.6363881
[14]
Dem, A., et al. (2008) Les cancers gynécologiques et mammaires à l’Institut du cancer de Dakar. Cahiers d’études et de recherches francophones/Santé, 18, 25-29. https://doi.org/10.1684/san.2008.0093
[15]
Karim, R., et al. (2013) Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte’s Innate Immune Response. PLOS Pathogens, 9, e1003384. https://doi.org/10.1371/journal.ppat.1003384
[16]
Saraiva, M. and O’Garra, A. (2010) The Regulation of IL-10 Production by Immune Cells. Nature Reviews Immunology, 10, 170-181. https://doi.org/10.1038/nri2711
[17]
Kaplan, D.E., et al. (2008) Peripheral Virus Specific T-Cell Interleukin-10 Responses Develop Early in Acute Hepatitis C Infection and Become Dominant in Chronic Hepatitis. Journal of Hepatology, 48, 903-913. https://doi.org/10.1016/j.jhep.2008.01.030
[18]
Rendleman, J., et al. (2014) IL10 Locus as q Biomarker of Melanoma Survival. Annals of Oncology, 25, 58-84. https://doi.org/10.1093/annonc/mdu326.73
[19]
Garbers, C., Aparicio-Siegmund, S. and RoseJohn, S. (2015) The IL-6/gp130/STAT3 Signaling Axis: Recent Advances towards Specific Inhibition. Current Opinion in Immunology, 34, 75-82. https://doi.org/10.1016/j.coi.2015.02.008
[20]
Woodworth, C.D. and Simpson, S. (1993) Comparative Lymphokine Secretion by Cultured Normal Human Cervical Keratinocytes, Papillomavirus-Immortalized, and Carcinoma Cell Lines. The American Journal of Pathology, 142, 1544-1555.
[21]
Malejczyk, J., Malejczyk, M. and Urbanski, A. (1991) Constitutive Release of IL6 by Human Papillomavirus Type 16 (HPV16)-Harboring Keratinocytes: A Mechanism Augmenting the NK-Cell-Mediated Lysis of HPV-Bearing Neoplastic Cells. Cellular Immunology, 136, 155-164. https://doi.org/10.1016/0008-8749(91)90390-W
[22]
Tatour, E., Gey, A. and Sastre-Garau, X. (1994) Analysis of Interleukin 6 Expression in Cervical Neoplasia Using a Quantative Polymerase Chain Reaction Assay: Evidence for Enhanced Interleukin 6 Gene Expression in Invasive Carcinoma. Cancer Research, 54, 6243-6248.
[23]
Chauhan, D., Kharbanda, S. and Ogata, A. (1997) Interleukin 6 Inhibits Fas-Induced Apoptosis and Stress-Activated Protein Kinase Activation in Multiple Myeloma Cells. Blood, 89, 227-234. https://doi.org/10.1182/blood.V89.1.227
[24]
Morel, S., et al. (2000) Processing of Some Antigens by the Standard Proteasome but Not by the Immunoproteasome Results in Poor Presentation by Dendritic Cells. Immunity, 12, 107-117. https://doi.org/10.1016/S1074-7613(00)80163-6
[25]
Lollini, P.L., et al. (1993) Inhibition of Tumor Growth and Enhancement of Metastasis after Transfection of the Gamma-Interferon Gene. International Journal of Cancer, 55, 320-329. https://doi.org/10.1002/ijc.2910550224
[26]
Sistigu, A., et al. (2014) Cancer Cell-Autonomous Contribution of Type I Interferon Signaling to the Efficacy of Chemotherapy. Nature Medicine, 20, 1301-1309.
[27]
Tepper, R.I., Pattengale, P.K. and Leder, P. (1989) Murine Interleukin 4 Displays Potent Anti-Tumor Activity in Vivo. Cell, 57, 503-512. https://doi.org/10.1016/0092-8674(89)90925-2
[28]
Michalaki, V., et al. (2004) Serum Levels of IL-6 and TNF-Alpha Correlate with Clinicopathological Features and Patient Survival in Patients with Prostate Cancer. British Journal of Cancer, 90, 2312-2316. https://doi.org/10.1038/sj.bjc.6601814
[29]
Monford, A., et al. (2019) The TNF Paradox in Cancer Progression and Immunotherapy. Frontiers in Immunology, 10, Article No. 1818. https://doi.org/10.3389/fimmu.2019.01818
